Get access

Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea

Authors

  • J. J. Wu,

    1. Department of Dermatology, University of California, Irvine, Irvine, CA, USA; and *Valeant Pharmaceuticals International, Costa Mesa, CA, USA
    Search for more papers by this author
  • G. D. Weinstein,

    1. Department of Dermatology, University of California, Irvine, Irvine, CA, USA; and *Valeant Pharmaceuticals International, Costa Mesa, CA, USA
    Search for more papers by this author
  • G. J. Kricorian,

    1. Department of Dermatology, University of California, Irvine, Irvine, CA, USA; and *Valeant Pharmaceuticals International, Costa Mesa, CA, USA
    Search for more papers by this author
  • T Kormeili,

    1. Department of Dermatology, University of California, Irvine, Irvine, CA, USA; and *Valeant Pharmaceuticals International, Costa Mesa, CA, USA
    Search for more papers by this author
  • J. L. McCullough

    1. Department of Dermatology, University of California, Irvine, Irvine, CA, USA; and *Valeant Pharmaceuticals International, Costa Mesa, CA, USA
    Search for more papers by this author

  • Conflict of interest: Dr Wu, Dr Weinstein, Dr Kormeili and Dr McCullough have no conflict of interest with the sponsor. Dr Kricorian is the Director of Medical Affairs at Valeant Pharmaceuticals International.

Dr Jashin J. Wu, MD, Department of Dermatology, C340 Medical Sciences, University of California, Irvine, Irvine, CA 92697-2400, USA.
E-mail: jjwu@uci.edu

Summary

Many patients with rosacea are unable to tolerate extended treatment periods with topical agents because of the unusually high skin sensitivity that often accompanies rosacea. Kinetin (N6-furfuryladenine) is a plant cytokinin that reportedly helps restore skin barrier function and may be useful to ameliorate the signs and symptoms of rosacea. The purpose of this open-label study was to determine the tolerance and efficacy of twice-daily application of kinetin 0.1% lotion for improving the signs and symptoms of mild to moderate facial rosacea. Subjects applied kinetin 0.1% lotion twice daily to the face, with daily use of a sunscreen of sun protection factor 30. Subjects were evaluated at baseline and at 4-week intervals for 12 weeks to assess efficacy and tolerance. Results of this study suggest that kinetin 0.1% lotion is a well-tolerated moisturizing lotion option for subjects with mild to moderate inflammatory rosacea.

Ancillary